trending Market Intelligence /marketintelligence/en/news-insights/trending/6qgdbapvmjsfnicx4ugktq2 content esgSubNav
In This List

DiaMedica Therapeutics implements 1-for-20 share consolidation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


DiaMedica Therapeutics implements 1-for-20 share consolidation

DiaMedica Therapeutics Inc. said it will implement a 1-for-20 consolidation of its outstanding common shares.

Shareholders approved the consolidation on Nov. 6.

Post-consolidation, the clinical-stage biopharmaceutical company will have about 7,856,875 common shares issued and outstanding.

The company's post-consolidation shares will begin trading on TSX Venture Exchange and the OTCQB marketplace on or about Nov. 15.

Minneapolis-based DiaMedica, which develops treatments for neurological and kidney diseases, is planning to list its shares on Nasdaq under the symbol DMAC.